カテゴリ： GlobalData, アメリカ, 企業調査

PharmaCyte Biotech Inc (PMCB)-製薬・医療分野：企業M&A・提携分析

◆英語タイトル：PharmaCyte Biotech Inc (PMCB) - Pharmaceuticals & Healthcare - Deals and Alliances Profile
◆商品コード：DATA8013334
◆発行会社（調査会社）：GlobalData
◆発行日：2017年11月28日
◆ページ数：85
◆レポート言語：英語
◆レポート形式：PDF
◆納品方法：Eメール
◆対象地域：アメリカ
◆産業分野：製薬・医療
◆販売価格オプション（消費税別）
Single UserUSD250 ⇒換算￥37,000見積依頼/購入/質問フォーム
Site License（同一事業所内共有可）USD500 ⇒換算￥74,000見積依頼/購入/質問フォーム
Enterprisewide License（複数事業所内共有可）USD750 ⇒換算￥111,000見積依頼/購入/質問フォーム
※販売価格オプションの説明はこちらで、ご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額（日本円）＋消費税＋配送料（Eメール納品は無料）」です。
※本体価格が￥30,000未満のレポートにつきましては、ハンドリングチャージ￥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日＋5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規販売代理店です。同社発行の企業調査レポートに関するお問い合わせは弊社までお願い致します。
※GlobalData社の概要はこちらでご確認いただけます。

このエントリーをはてなブックマークに追加
LINEで送る


【レポートの概要】

Summary
PharmaCyte Biotech Inc (PharmaCyte), formerly Nuvilex Inc is a clinical stage biotechnology company that develops and commercializes treatments for cancer and diabetes. The company’s technology is used for the treatment of advanced and inoperable pancreatic cancer, and diabetes. It develops Cell-in-a-Box cellulose-based live cell encapsulation technology. PharmaCyte’s treatment for pancreatic cancer consists of the combination of live cells encapsulated using Cell-in-a-Box technology together with low doses of the anticancer prodrug ifosfamide. It conducts research in the areas of live cell encapsulation technology, pancreatic cancer, diabetes, cannabinoids and cancer and breast cancer, among others. PharmaCyte is headquartered in Laguna Hills, California, the US.

PharmaCyte Biotech Inc (PMCB) – Pharmaceuticals & Healthcare – Deals and Alliances Profile provides you comprehensive data and trend analysis of the company’s Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals – Analysis of the company’s financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year – Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type – Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region – Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector – Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals – Information on the company’s major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description – A brief description of the company’s operations.
- Key Employees – A list of the key executives of the company.
- Important Locations and Subsidiaries – A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors – A list of the key competitors of the company.
- Key Recent Developments – A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company’s financial deals that enable you to understand the company’s expansion/divestiture and fund requirements
- The profile enables you to analyze the company’s financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company’s business segments’ expansion / divestiture strategy
- The profile presents deals from the company’s core business segments’ perspective to help you understand its corporate strategy.

Access elaborate information on the company’s recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company’s key financial metrics and ratios.

Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

【レポートの目次】

Table of Contents
Table of Contents 3
List of Tables 5
List of Figures 5
PharmaCyte Biotech Inc, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 6
PharmaCyte Biotech Inc, Pharmaceuticals & Healthcare Deals By Type, 2011 to YTD 2017 7
PharmaCyte Biotech Inc, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 8
PharmaCyte Biotech Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2011 to YTD 2017 9
PharmaCyte Biotech Inc, Medical Devices Deals, 2011 to YTD 2017 10
PharmaCyte Biotech Inc, Pharmaceuticals & Healthcare, Deals Summary, 2011 to YTD 2017 11
PharmaCyte Biotech Inc, Pharmaceuticals & Healthcare, Deal Details 12
Asset Purchase 12
Nuvilex Acquires Rights To Live-Cell Encapsulation Technology For Diabetes From SG Austria 12
Nuvilex Acquires Pancreatic Cancer Treatment Technology 13
Partnerships 14
PharmaCyte Biotech Partners with Translational Drug Development and Clinical Network Services 14
PharmaCyte Biotech Enters into Co-Development Agreement with University of Technology Sydney 15
Licensing Agreements 16
Nuvilex Enters into Licensing Agreement with University of Technology Sydney 16
Equity Offering 17
PharmaCyte Biotech Raises USD1 Million in Private Placement of shares 17
Nuvilex to Raise up to USD50 Million in Public Offering of Shares 18
Nuvilex Completes First Tranche Of Private Placement Of Shares For US$2 Million 19
Nuvilex Competes Private Placement Of Securities For US$1.5 Million 20
Acquisition 21
Nuvilex Acquires 14.5% Stake In SGAustria, Life Science Company 21
Nuvilex Acquires Bio Blue Bird For US$1.5 Million 22
PharmaCyte Biotech Inc – Key Competitors 23
PharmaCyte Biotech Inc – Key Employees 24
PharmaCyte Biotech Inc – Locations And Subsidiaries 25
Head Office 25
Other Locations & Subsidiaries 25
Recent Developments 26
Corporate Communications 26
Oct 10, 2017: PharmaCyte Biotech Appoints Dr. Raymond Tong to Board of Directors 26
Jul 26, 2017: PharmaCyte Biotech Appoints Dr. Linda S. Sher as Chief Medical Officer 27
Jul 10, 2017: PharmaCyte Biotech Appoints Dr. Michael M. Abecassis to Board of Directors 29
May 02, 2017: PharmaCyte Biotech Appoints Thomas Yuen to Board of Directors 30
Apr 03, 2017: PharmaCyte Biotech Appoints Dr. Mark Rabe Director of Cannabis Program Development 31
Legal and Regulatory 32
Nov 16, 2017: British Columbia Securities Commission Revokes Cease Trade Order on PharmaCyte Biotech Securities 32
Government and Public Interest 34
Feb 23, 2017: First Ever Cannabis-Based ETF to Include PharmaCyte Biotech, Abbott Laboratories, and GW Pharmaceuticals 34
Product News 35
Dec 01, 2016: PharmaCyte Biotech Moves Closer to Enrolling Patients in Pancreatic Cancer Clinical Trial 35
Oct 17, 2017: PharmaCyte Biotech Research Identifies Enzyme Activity for Cannabinoid-Based Therapy to Fight Cancer 37
10/10/2016: PharmaCyte Biotech Cannabinoid Research Shows Promise for Success 38
07/07/2016: PharmaCyte Biotech Uses “Artificial Liver” to Treat Advanced Pancreatic Cancer 39
Jul 05, 2016: PharmaCyte’s Research on Medical Uses of Cannabinoids Supported by Recent Scientific Article 40
05/26/2016: PharmaCyte Biotech to Present Clinical Trial at Marcum MicroCap, ASCO and BIO International Conferences 41
04/25/2016: PharmaCyte Biotech’s Live-Cell Encapsulation Facility is Commissioned for GMP Manufacture 42
04/18/2017: PharmaCyte Biotech Discusses Future of Cannabis Research Program, Competitors and More with Program’s Director 43
04/10/2017: PharmaCyte Biotech’s Cannabis Research Program Sees Significant Progress in University of Northern Colorado Presentations 45
03/03/2016: PharmaCyte Biotech Reports on Audit of Live-Cell Encapsulation Facility by Chamow & Associates 47
03/01/2016: PharmaCyte Biotech Addresses Development of Targeted Cannabinoid Chemotherapy 48
02/26/2016: PharmaCyte Biotech Pancreatic Cancer Treatment to Target Recently Identified Forms of Pancreatic Cancer 49
Feb 13, 2017: PharmaCyte Biotech Moves Closer to Filing IND with Naming of Comparator Arm for Upcoming Clinical Trial and Discusses Pivotal Trial Opportunity 50
Jan 25, 2016: PharmaCyte Executives Meet With Translational Drug Development to Advance Pancreatic Cancer Clinical Trial 52
01/24/2017: PharmaCyte Going Head to Head with Eli Lillys Pancreatic Cancer Drug in New Clinical Trial 53
01/19/2016: PharmaCyte Biotech Introduces Cell-in-a-Box as a Novel Treatment for Pancreatic Cancer and Potential Cure for Type 1 Diabetes 55
Jan 04, 2016: PharmaCyte Biotech Outlines 2016 Milestones as Its Pancreatic Cancer Treatment Moves Into a Clinical Trial 56
Product Approvals 57
Feb 13, 2017: PharmaCyte Biotech Moves Closer to Filing IND with Naming of Comparator Arm for Upcoming Clinical Trial and Discusses Pivotal Trial Opportunity 57
Jan 30, 2017: PharmaCyte Biotech Retains Facet Life Sciences to Guide Pancreatic Cancer Therapy Development Lifecycle with FDA 59
Jan 04, 2017: PharmaCyte Biotech Announces Pre-IND Meeting Date with FDA 60
Dec 15, 2016: PharmaCyte Biotech Submits Pre-IND Meeting Package to FDA 61
Nov 29, 2016: PharmaCyte Biotech Granted FDA Pre-IND Meeting for Pancreatic Cancer Therapy 62
Nov 16, 2016: PharmaCyte Biotech Now Awaits U.S. FDA to Advance Pancreatic Cancer Therapy into Pivotal Clinical Trial 63
Nov 01, 2016: PharmaCyte Biotech Requests Pre-IND Meeting with FDA for its Pancreatic Cancer Clinical Trial 65
Apr 08, 2016: PharmaCyte Biotech’s Encapsulation Facility for Pancreatic Cancer Therapy Deemed Suitable by Thai FDA 66
Clinical Trials 67
Feb 21, 2017: PharmaCyte Biotech Discusses Patient Enrollment and TD2s Role in Upcoming Clinical Trial 67
Dec 12, 2016: PharmaCyte Biotech Secures Funding Opportunity for Pancreatic Cancer Clinical Trial 69
Dec 07, 2016: PharmaCyte Biotech Discusses Upcoming Clinical Trial in Pancreatic Cancer with First Principal Investigator 71
Dec 01, 2016: PharmaCyte Biotech Moves Closer to Enrolling Patients in Pancreatic Cancer Clinical Trial 73
Oct 24, 2016: PharmaCyte Biotech Selects Dr. Manuel Hidalgo as Principal Investigator for Its Pancreatic Cancer Clinical Trial 75
Jun 23, 2016: PharmaCyte Biotech Releases Medical and Scientific Discussion from 2016 ASCO Annual Meeting 76
May 24, 2016: PharmaCyte Biotech to Engage Principal Investigator for Clinical Trial in Pancreatic Cancer 77
May 05, 2016: PharmaCyte Biotech Clears Major Milestone on Path to FDA Clinical Trial 78
Apr 06, 2016: PharmaCyte Biotech’s CEO Explains How New Clinical Trial Design Changed the GMP Certification Process 80
Mar 31, 2016: PharmaCyte Biotech Finalizes Design of Pancreatic Cancer Clinical Trial and Identifies Trial Sites under Consideration 81
Feb 24, 2016: PharmaCyte Biotech on Schedule for 2016 Cancer Clinical Trial in Pancreatic Cancer 82
Feb 22, 2016: PharmaCyte Biotech Issues Update on Preparations for Its Pancreatic Cancer Clinical Trial 83
Appendix 85
Methodology 85
About GlobalData 85
Contact Us 85
Disclaimer 85

List of Tables
PharmaCyte Biotech Inc, Pharmaceuticals & Healthcare, Key Facts, 2017 2
PharmaCyte Biotech Inc, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 6
PharmaCyte Biotech Inc, Pharmaceuticals & Healthcare Deals By Type, 2011 to YTD 2017 7
PharmaCyte Biotech Inc, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 8
PharmaCyte Biotech Inc, Deals By Therapy Area, 2011 to YTD 2017 9
PharmaCyte Biotech Inc, Medical Devices Deals, 2011 to YTD 2017 10
PharmaCyte Biotech Inc, Pharmaceuticals & Healthcare, Deals Summary, 2011 to YTD 2017 11
Nuvilex Acquires Rights To Live-Cell Encapsulation Technology For Diabetes From SG Austria 12
Nuvilex Acquires Pancreatic Cancer Treatment Technology 13
PharmaCyte Biotech Partners with Translational Drug Development and Clinical Network Services 14
PharmaCyte Biotech Enters into Co-Development Agreement with University of Technology Sydney 15
Nuvilex Enters into Licensing Agreement with University of Technology Sydney 16
PharmaCyte Biotech Raises USD1 Million in Private Placement of shares 17
Nuvilex to Raise up to USD50 Million in Public Offering of Shares 18
Nuvilex Completes First Tranche Of Private Placement Of Shares For US$2 Million 19
Nuvilex Competes Private Placement Of Securities For US$1.5 Million 20
Nuvilex Acquires 14.5% Stake In SGAustria, Life Science Company 21
Nuvilex Acquires Bio Blue Bird For US$1.5 Million 22
PharmaCyte Biotech Inc, Key Competitors 23
PharmaCyte Biotech Inc, Key Employees 24
PharmaCyte Biotech Inc, Subsidiaries 25

★海外企業調査レポート[PharmaCyte Biotech Inc (PMCB)-製薬・医療分野：企業M&A・提携分析]についてメールでお問い合わせはこちら
■おすすめ企業レポート■
  • Cingulate Therapeutics LLC：製薬・医療：M&Aディール及び事業提携情報
    Summary Cingulate Therapeutics LLC (Cingulate) is a clinical stage biopharmaceutical company that develops new drug products for the treatment of attention deficit and hyperactivity disorder. The company’s pipeline products comprise CTX-1301 and CTX-1302 utilize precision timed release (PTR) drug de …
  • Prevas AB (PREV B)：企業の財務・戦略的SWOT分析
    Prevas AB (PREV B) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and th …
  • McDonald’s Australia Limited：企業の戦略的SWOT分析
    McDonald's Australia Limited - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major produc …
  • Monsanto Company (MON)-製薬・医療分野：企業M&A・提携分析
    Summary Monsanto Company (Monsanto) is an agricultural products manufacturing company. It develops and delivers agricultural products to support farmers all around the world. The company develops biotechnology traits that assist farmers in controlling insects and weeds. Monsanto also provides other …
  • Tyser & Co Ltd：企業の戦略的SWOT分析
    Tyser & Co Ltd - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and service …
  • Mytrus Inc-製薬・医療分野：企業M&A・提携分析
    Summary Mytrus Inc (Mytrus) is an e-clinical technology company that specializes in patient-centered electronic informed consent and data collection tools. The company’s technology includes Enroll, an electronic informed consent and patient enrollment system for clinical trials. Mytrus develops new …
  • American States Water Company (AWR)：企業の財務・戦略的SWOT分析
    Summary American States Water Company (AWR) is a utility service provider that offers water, wastewater and electric services. The utility provides operation, construction management and maintenance services for water and wastewater systems located on military bases across the US. It offers water se …
  • Amil Assistencia Medica Internacional S/A：企業の戦略・SWOT・財務情報
    Amil Assistencia Medica Internacional S/A - Strategy, SWOT and Corporate Finance Report Summary Amil Assistencia Medica Internacional S/A - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SW …
  • KSK Energy Ventures Ltd (KSK)：電力：M&Aディール及び事業提携情報
    Summary KSK Energy Ventures Ltd (KSKEVL), a subsidiary of KSK Energy Ltd, is a power project development company that carries out development, operations and maintenance of power projects in India. The company operates power project at multiple phases including projects in planning phase, project un …
  • Mobile Telesystems
    Mobile Telesystems - Strategy, SWOT and Corporate Finance Report Summary Mobile Telesystems - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and …
  • Siemens AG (SIE)：企業の財務・戦略的SWOT分析
    Siemens AG (SIE) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and the …
  • CohBar Inc (COB.U)：企業の財務・戦略的SWOT分析
    Summary CohBar Inc (CohBar) is a developer of mitochondria based therapeutics. The company develops a class of drugs to treat a wide range of diseases associated with aging and metabolic dysfunction such as non-alcoholic steatohepatitis, obesity, type 2 diabetes, cancer, cardiovascular disease and C …
  • Grupo Financiero Galicia S.A. (GGAL3)：企業の財務・戦略的SWOT分析
    Grupo Financiero Galicia S.A. (GGAL3) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths an …
  • Lloyds Bank Private Banking Limited：企業の戦略・SWOT・財務情報
    Lloyds Bank Private Banking Limited - Strategy, SWOT and Corporate Finance Report Summary Lloyds Bank Private Banking Limited - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, …
  • Paymark：企業の戦略的SWOT分析
    Paymark - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and services. This …
  • Mega International Commercial Bank Co Ltd：企業の戦略・SWOT・財務情報
    Mega International Commercial Bank Co Ltd - Strategy, SWOT and Corporate Finance Report Summary Mega International Commercial Bank Co Ltd - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SW …
  • Dedeman Hotels & Resorts International：企業の戦略・SWOT・財務情報
    Dedeman Hotels & Resorts International - Strategy, SWOT and Corporate Finance Report Summary Dedeman Hotels & Resorts International - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT ana …
  • Oil and Natural Gas Corporation Ltd (ONGC)-エネルギー分野：企業M&A・提携分析
    Summary Oil and Natural Gas Corporation Ltd (ONGC) is an integrated oil and gas company. It explores for and produces oil and natural gas; refines crude oil; and markets and distributes petroleum products. The company's product portfolio includes crude oil, natural gas, liquefied natural gas, naphth …
  • Green Dot Corporation：企業の戦略・SWOT・財務分析
    Green Dot Corporation - Strategy, SWOT and Corporate Finance Report Summary Green Dot Corporation - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerin …
  • Queen Mary University of London-製薬・医療分野：企業M&A・提携分析
    Summary Queen Mary University of London (Queen Mary), formerly Queen Mary and Westfield College, a subsidiary of University of London, is a research university that offers undergraduate and postgraduate education; and research programs. The university provides graduation and education services in ar …

◆H&Iグローバルリサーチ株式会社のお客様（例）◆